Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01065935




Registration number
NCT01065935
Ethics application status
Date submitted
5/02/2010
Date registered
10/02/2010
Date last updated
5/02/2018

Titles & IDs
Public title
Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Scientific title
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Secondary ID [1] 0 0
ALN-RSV01-109
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infections 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ALN-RSV01
Treatment: Drugs - Normal Saline

Active Comparator: ALN-RSV01 -

Placebo Comparator: Normal saline -


Treatment: Drugs: ALN-RSV01
Administered by nebulization once daily for 5 days

Treatment: Drugs: Normal Saline
Administered by nebulization once daily for 5 days
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The occurrence of new or progressive BOS grade 0p through 3 in RSV-infected lung transplant recipients
Timepoint [1] 0 0
180 days after randomization
Secondary outcome [1] 0 0
Proportion of patients with FEV1 >80% of pre-infection baseline value
Timepoint [1] 0 0
90 and 180 days after randomization
Secondary outcome [2] 0 0
RSV symptoms as measured by mean cumulative daily total symptom score
Timepoint [2] 0 0
14 days after randomization
Secondary outcome [3] 0 0
Viral load as measured by viral area under the curve (AUC)
Timepoint [3] 0 0
6 days after randomization
Secondary outcome [4] 0 0
All cause mortality
Timepoint [4] 0 0
Throughout the study

Eligibility
Key inclusion criteria
- Single or bilateral lung transplant recipients

- Confirmed RSV infection

- Greater than 90 days post current lung transplant

- Rejection free for a minimum of 30 days
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Known viral, bacterial, or fungal respiratory co-infection at the time of RSV
diagnosis

- Bronchiolitis obliterans syndrome (BOS) Grade 3 or any BOS with FEV1 that has not been
stable for at least 3 months

- Use of alemtuzumab within 9 months prior to screening, anti-thymocyte globulin (ATG)
within 90 days of screening or prednisone or equivalent as maintenance therapy

- Active treatment for acute graft rejection

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/05/2012
Sample size
Target
Accrual to date
Final
87
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Clinical Site - Darlinghurst
Recruitment hospital [2] 0 0
Clinical Site - Adelaide
Recruitment hospital [3] 0 0
Clinical Site - Melbourne
Recruitment hospital [4] 0 0
Clinical Site - Perth
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment postcode(s) [3] 0 0
3004 - Melbourne
Recruitment postcode(s) [4] 0 0
6001 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
Tennessee
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
Austria
State/province [15] 0 0
Vienna
Country [16] 0 0
Canada
State/province [16] 0 0
Alberta
Country [17] 0 0
Canada
State/province [17] 0 0
Ontario
Country [18] 0 0
France
State/province [18] 0 0
Paris
Country [19] 0 0
France
State/province [19] 0 0
Strasbourg Cedex
Country [20] 0 0
Germany
State/province [20] 0 0
Berlin
Country [21] 0 0
Germany
State/province [21] 0 0
Essen
Country [22] 0 0
Germany
State/province [22] 0 0
Hamburg
Country [23] 0 0
Germany
State/province [23] 0 0
Hannover
Country [24] 0 0
Germany
State/province [24] 0 0
Homburg/Saar
Country [25] 0 0
Germany
State/province [25] 0 0
Leipzig

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Alnylam Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To evaluate the efficacy and safety of ALN-RSV01 plus standard of care in RSV infected lung
transplant patients
Trial website
https://clinicaltrials.gov/ct2/show/NCT01065935
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Martin Zamora, MD
Address 0 0
University of Colorado, Denver
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01065935